What would a migraine headache look like as art? That’s what Allergan is asking sufferers in a new campaign for chronic migraine awareness.

The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week.

Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected.

​​​​​​​Amid a busy time in Washington, new data on pharmaceutical lobbying show which groups and companies have boosted their spending so far this year.

Facing stepped-up competition for its critical MS franchise, Biogen CEO Michel Vounatsos says his company's ready to try some "innovative" payer…

Yet another key Teva exec could be bowing out in the company’s time of need—and that’s CFO Eyal Desheh.

Novartis’ worst may be behind it—at least, it seemed so to some analysts following Tuesday’s first-quarter earnings announcement.

Investors were in the mood for good news from Eli Lilly—and they got a bit of it in its first-quarter earnings report, even as pipeline worries cast a cloud…

Sanofi has ratcheted up the legal pressure on Mylan with a lawsuit claiming the EpiPen maker abused its monopoly position to “squelch” competition, including…